Shilpa Medicare Limited announced its financial results for the first quarter of FY27 (1QFY27), reporting its highest-ever quarterly revenue at ₹469 crore, a significant 43% increase year-on-year. The company also achieved its highest quarterly EBITDA of ₹139 crore, up 42% YoY, with EBITDA margins holding strong at 30%. Profit After Tax (PAT) more than doubled, increasing by 115% YoY to ₹101 crore.
Shilpa Medicare Reports Record Quarterly Financials for 1QFY27
Shilpa Medicare Limited has announced its financial results for the first quarter ended June 30, 2026 (1QFY27), showcasing a period of robust growth and operational strength. The company achieved its highest-ever quarterly revenue, reaching ₹469 crore, which represents a substantial year-on-year (YoY) increase of 43%. This impressive revenue growth was attributed to strong performance across all its key business verticals.
Strong EBITDA and Profit Growth
Further underscoring the company’s performance, Shilpa Medicare also posted its highest-ever quarterly EBITDA, amounting to ₹139 crore. This figure marks a significant 42% increase compared to the same period last year. The EBITDA margins remained healthy at 30%, demonstrating effective cost management and operational leverage. The company’s Profit After Tax (PAT) witnessed a remarkable surge of 115% YoY, reaching ₹101 crore.
Revenue Break-up Highlights Diversified Growth
The revenue break-up for 1QFY27 indicates a diversified contribution from its business segments. The API segment contributed the largest share at 47%, followed by Formulations at 42%, and Biologics at 11%. This balanced revenue stream highlights Shilpa Medicare’s strategic positioning across different areas of the pharmaceutical industry.
Key Financial Highlights (Consolidated)
- Total Revenue: ₹469 crore (YoY +43%)
- Gross Profit: ₹334 crore (YoY +34%)
- GP Margin: 71%
- EBITDA: ₹139 crore (YoY +42%)
- EBITDA Margin: 30%
- Reported PAT: ₹101 crore (YoY +115%)
- Adj. PAT: ₹101 crore (YoY +115%)
The management commentary highlighted the company’s strong start to FY27, driven by consistent improvement across its three key verticals. Shilpa Medicare emphasized its integrated organization strategy, combining robust R&D, manufacturing capabilities, and a growing portfolio of complex products. The company also noted a significant credit rating upgrade from A+ to AA-, reflecting its enhanced financial stability and prudent business practices.
Source: BSE
